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TRAIL-induced variation of cell signaling states provides
nonheritable resistance to apoptosis
Reema Baskar1,2,* , Harris G Fienberg2,3,*, Zumana Khair2 , Patricia Favaro2, Sam Kimmey2,4 , Douglas R Green5,
Garry P Nolan6, Sylvia Plevritis1, Sean C Bendall2,3
TNFα-related apoptosis-inducing ligand (TRAIL), specifically
initiates programmed cell death, but often fails to eradicate all cells,
making it an ineffective therapy for cancer. This fractional killing
is linked to cellular variation that bulk assays cannot capture.
Here, we quantify the diversity in cellular signaling responses to
TRAIL, linking it to apoptotic frequency across numerous cell
systems with single-cell mass cytometry (CyTOF). Although all
cells respond to TRAIL, a variable fraction persists without ap-
optotic progression. This cell-specific behavior is nonheritable
where both the TRAIL-induced signaling responses and frequency
of apoptotic resistance remain unaffected by prior exposure. The
diversity of signaling states upon exposure is correlated to TRAIL
resistance. Concomitantly, constricting the variation in signaling
response with kinase inhibitors proportionally decreases TRAIL
resistance. Simultaneously, TRAIL-induced de novo translation in
resistant cells, when blocked by cycloheximide, abrogated all
TRAIL resistance. This work highlights how cell signaling diversity,
and subsequent translation response, relates to nonheritable
fractional escape from TRAIL-induced apoptosis. This refined
view of TRAIL resistance provides new avenues to study death
ligands in general.
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Introduction
Chemotherapeutic drug resistance is one of the critical impedi-
ments to successful malignant tumor treatment in humans. Con-
ventional thinking is that a subset of tumor cells variably persists in
the face of cytotoxic drugs because of preexisting genetic differ-
ences that confer a cell state with a selective survival advantage.
However, it has been shown that genetically identical tumor cells
display variable cell states that allow differences in response to
chemotherapy drug, thereby highlighting a nongenetic basis of
resistance that has yet to be extensively explored in human cancers
(Brock et al, 2009; Niepel et al, 2009). Variable cell states in tumor
cells arise partly because of differential chromatin accessibility,
which results in different transcriptomes (Cohen et al, 2008; Shaffer
et al, 2017; Litzenburger et al, 2017). Further intercellular differences in
translation and degradation drive stochastic differences in the
proteome and lead to different cell states despite genetical ho-
mogeneity (Brock et al, 2009). In the case of resistance to TNF-related
apoptosis-inducing ligand (TRAIL), stochastic variation in levels of
proteins involved in apoptosis has been implicated as a nongenetic
mechanism of resistance (Spencer et al, 2009; Bertaux et al, 2014).
TRAIL is an endogenous ligand of the TNF family that has been
shown to target and induce apoptosis in tumor cells selectively
(Wiley et al, 1995; Ashkenazi et al, 1999; Walczak et al, 1999). It binds
death receptors (DR4/5) to initiate the formation of death-inducing
signaling complexes (DISCs) with the recruitment of adaptor protein
FADD (FAS-associated death domain protein) (Kischkel et al, 1995).
FADD subsequently activates high levels of pro-caspase 8 and 10
for eventual cell death in type I cells (Boatright et al, 2003; Kantari
& Walczak, 2011). In type II cells, additional Bid cleavage and pro-
apoptotic Bcl2 family members are required for mitochondrial outer
membrane permeabilization and cell death (O¨zo¨ren & El-Deiry, 2002;
Rudner et al, 2005). Recombinant TRAIL ligand and monoclonal ag-
onist antibodies to death receptor (DR4/5) were developed as cancer
therapeutics but were found to be clinically ineffective, likely because
of widespread resistance to TRAIL-induced apoptosis (Herbst et al,
2010; Holland, 2014).
Tumor cells exhibit fractional cell death when exposed to TRAIL,
even at saturating levels in vitro, with only a proportion of cells
inducing apoptosis (Flusberg et al, 2013; Pavet et al, 2014; Roux et al,
2015). Furthermore, the observed resistance was found to be
transient, as tumor cells previously treated with TRAIL demonstrate
similar fractional death upon subsequent TRAIL exposure (Spencer
et al, 2009; Flusberg et al, 2013). This transient fractional killing is in
part explained by the double role of TRAIL in apoptosis canonically
as well as in noncanonical, pro-survival, pro-inflammatory, and
proliferative signaling (Azijli et al, 2013; Flusberg et al, 2013; Flusberg
1Cancer Biology Program, Stanford University School of Medicine, Stanford, CA, USA 2Department of Pathology, Stanford University School of Medicine, Stanford, CA,
USA 3Immunology Program, Stanford University School of Medicine, Stanford, CA, USA 4Developmental Biology Program, Stanford University School of Medicine,
Stanford, CA, USA 5St. Jude Children’s Research Hospital, Memphis, TN, USA 6Baxter Laboratory, Stanford University School of Medicine, Stanford, CA, USA
Correspondence: bendall@stanford.edu
*Reema Baskar and Harris G Fienberg contributed equally to this work.
© 2019 Baskar et al. https://doi.org/10.26508/lsa.201900554 vol 2 | no 6 | e201900554 1 of 16
& Sorger, 2015; Shlyakhtina et al, 2017). Key transcription factor NF-
κB is activated downstream of TRAIL by DISC phosphorylation and
subsequent degradation of NF-κB agonist, IκBα (Chaudhary et al,
1997; Jeremias & Debatin, 1998; Ehrhardt et al, 2003; Luo et al, 2005).
Other noncanonical signaling pathways such as ERK, Akt, p38, Jnk,
and mTOR have been implicated in resistance to TRAIL-induced
apoptosis (Azijli et al, 2013; Kim et al, 2000; Lee et al, 2002;
Mühlenbeck et al, 1998; Panner et al, 2005; Vaculova´ et al, 2006;
Xu et al, 2010; Zauli et al, 2005). However, much of this work has been
carried out in different cancer cell types and bulk populations. The
variety of cell states present before and after TRAIL exposure as well
as critical signaling modalities that might be conserved across
cancer types has yet to be interrogated.
In addition to survival pathway activation, fractional killing by
TRAIL has also been explained by variation in pro and anti-apoptotic
protein abundance in tumor cells because of genetic aberrations or
nongenetic mechanisms (Zhang & Fang, 2005). Studies characterized
nongenetic mechanisms of variation in levels of anti-apoptotic pro-
tein cellular FLICE (c-FLIP), which binds to FADD and prevents for-
mation of DISC, in spatial organization of DR4/5 and in rate and
duration of initiator caspase activation by DISC (French et al, 2015;
Marconi et al, 2013; Roux et al, 2015; Twomey et al, 2015). Recent work
indicates that multiple mechanisms might be at play simultaneously
to result in intercellular variation and, therefore, cell states of re-
sistance (Ramirez et al, 2016; Salgia & Kulkarni, 2018). This underlines
the need for a single-cell approach to capture multi-dimensional
cell states. New single-cell proteomic technologies, such as mass
cytometry, allow us to identify apoptotic and survival cell states in a
multiplexed and high-throughput fashion upon TRAIL exposure and
analyze the intercellular variation that might be driving resistance
(Bendall et al, 2011; Fienberg & Nolan, 2014).
To that end, we interrogated TRAIL responsiveness across 10 human
cell lines, representing a multitude of cell lineages, under several
experimental conditions; followed by simultaneous, single-cell in-
terrogation of canonical and noncanonical apoptotic and survival
signaling pathways downstream of TRAIL with mass cytometry. This
enabled us to probe multiple layers of the cellular response to
TRAIL, including tracking of crucial kinase signal transduction,
apoptotic induction, cell cycle status, and de novo protein syn-
thesis, as they relate to apoptotic escape. We show that each tumor
cell line has a different level of fractional killing and surprisingly
have distinct yet conserved signaling responses to TRAIL. We
highlight the role of cell-to-cell variation in the survival signaling
pathways in TRAIL resistance for the first time, paralleling variation
found in the canonical apoptotic induction pathways (Spencer et al,
2009). We also show for the first time that the abundance of TRAIL
receptor 1 (death receptor 4 [DR4]) on the cell surface before TRAIL
exposure could dictate noncanonical response and, therefore,
resistance to TRAIL across cell lines.
Cellular heterogeneity of tumors and its involvement in de-
veloping resistance to chemotherapies is known, but we are yet to
quantify it robustly and decode the underlying conserved mech-
anisms that are driving this cell-to-cell variation (Fallahi-Sichani
et al, 2013; Sun & Yu, 2015). To quantify this, we used Shannon
diversity index as a multidimensional signaling heterogeneity
metric to analyze the effect of TRAIL on signaling states in cancer
cells. We then altered the signaling diversity by reducing the
permissible signaling states of resistance using inhibitors to critical
signaling pathways during TRAIL treatment. Importantly, we found
that the altered signaling diversity inversely correlates significantly
with level of resistance to different combination therapies. Fur-
thermore, through simultaneous application of a novel single-cell
translation assay, we found TRAIL-induced de novo protein syn-
thesis in these same resistant cells. A specific, short-term blockade
of this with a sub-cytotoxic dose of cycloheximide could effectively
abrogate all TRAIL resistance, resulting in apoptosis of all cells
treated. Collectively, this work highlights the integral role of variation
in a noncanonical signaling pathway that seems to lead to translation
of protein factors that contribute to a nongenetic mechanism of
resistance to TRAIL-induced apoptosis. This lays the groundwork for
building comprehensive models of TRAIL resistance which in-
corporates single-cell readouts of apoptosis, survival signaling, and
cell physiology activity.
Results
Cells variably persist in TRAIL across cancer lines
TRAIL-induced apoptosis progresses asynchronously over hours,
engaging the canonical external apoptotic pathway as well as the
noncanonical survival signaling pathways (Flusberg & Sorger, 2015;
Shlyakhtina et al, 2017). It is also known to interact with the cell cycle
processes of tumor cells (Ehrhardt et al, 2012, 2013). To gain a
systems-level perspective on TRAIL resistance, we treated 10 cancer
cell lines representing varied cancer types with TRAIL and analyzed
their single-cell responses across all three processes using a panel
of 30 markers covering apoptotic response, signaling response, cell
cycle status, and translation rate with mass cytometry (Fig 1A and
Table S1) (Bendall et al, 2011).
We profiled the apoptotic status of tumor cells with antibodies to
cleaved caspase 3 (cCasp3) and cleaved poly (ADP-ribose) poly-
merase (cPARP). In HeLa C9 and NCIH460 cell lines, the percentage
of viable, non-apoptotic cells decreased with increasing exposure
to TRAIL (Figs 1B and S1A and B). Most viable cells moved out of the
non-apoptotic gate (cCasp3low and cPARPlow), whereas a proportion
of cells remained and exhibited the fractional killing phenomenon
(Figs 1B and S1A and B, black arrow). Interestingly, even at the level
of apoptotic reporters, HeLa C9 and NCIH460 cells have different
patterns of progression with HeLa C9 cells having a more contin-
uous increase in cCasp3 and cPARP (Figs 1B and S1B). Even with this
trend, the proportion of non-apoptotic cells levels out after
reaching a threshold around 5–7 h, despite continued TRAIL ex-
posure till 24 h (Fig 1C, black line). Moreover, this phenomenon of
fractional killing has even been observed with increasing con-
centration of TRAIL (Flusberg et al, 2013). Fractional killing occurs
despite altering the treatment duration or dosage of TRAIL which
hints at an underlying conserved mechanism of resistance at play.
To better understand what might be underlying this phenom-
enon, we investigated the level of fractional killing by TRAIL across
cancer types with 10 different cancer cell lines (Fig 1D). We cal-
culated a survivor quotient (SQ, ratio of percentage of non-apoptotic
cells after TRAIL treatment to the percentage before treatment) to
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Figure 1. Cell type–specific persistence in TRAIL-induced apoptosis.
(A) Overview of experimental pipeline. 10 different cancer cell lines representing different cancer types were treated with 50 ng/ml recombinant TRAIL and harvested
for analysis onmass cytometry after intracellular staining with metal isotope-conjugated antibodies to apoptotic, survival signaling, and cell cycle proteins. (B) Live HeLa
C9 cells were gated based on cisplatin for live/dead staining (Fienberg et al, 2012). Canonical apoptosis markers, cleaved caspase 3 (cCasp3), and cPARP were captured on
live HeLa C9 cells with increasing exposure to TRAIL. The percentage of live cells in the black non-apoptotic gate is indicated. The black arrows visualize direction of
movement of population with time. (C) The percentage of non-apoptotic HeLa C9 cells (cCasp3low and cPARPlow) is tracked from 0–24 h of treatment with TRAIL. The dotted
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quantify the level of resistance to TRAIL-induced apoptosis after 6 h
of TRAIL treatment. The different cancer types have highly varying
levels of apoptotic resistance, as signified by the varying SQ (Fig 1D,
green value). Previous work suggested that endogenous preexisting
levels of apoptotic regulators, such as DR4 and c-FLIP, might explain
the differential levels of resistance (French et al, 2015; Li et al, 2011;
Zang et al, 2014; Zong et al, 2009).
To explore this possibility, we captured the abundance of DR4
protein on the cell surface membrane of 11 endogenous cell lines
using flow cytometry after validating the antibody on mRNA level-
based positive and negative cell line controls (Figs 1E, and S1E and F).
The level of DR4 differed between cell lines and did not show
high variation within each cell line (Figs 1E and S1F). We correlated
the level of DR4 protein to our calculated SQ across cell lines and
interestingly found a significant positive correlation indicating that
higher levels of DR4 corresponded to greater resistance to TRAIL-
induced apoptosis (Fig 1F). Similarly, we show a positive correlation
between SQ and mRNA levels of TNFRSF10A, given mRNA and protein
abundance levels of DR4 are highly correlated (Fig S1C and D). This
strongly highlights the need to interrogate the noncanonical response
to TRAIL binding DR4 as it results in a non-apoptotic cellular response
over apoptosis.
All the 10 cell lines we tested have a proportion of viable, non-
apoptotic cells remaining after 6 h of TRAIL treatment (Fig 1D).
However, like the pattern of the apoptotic factors cCasp3 and
cPARP, these resistant cells did not respond similarly to TRAIL with
respect to regulatory cell signaling (Fig 1E). For example, phos-
phorylation of ribosomal protein S6 is a known mediator of TRAIL
signaling and works in the mTOR pathway to primarily regulate
translation (Jeon et al, 2008; Panner et al, 2005; Sridharan and Basu,
2011). It has been implicated in other drug resistance phenomenon
as well and highlights the role of translation in acquisition of re-
sistance (Sun et al, 2014; Gao et al, 2018). Levels of phosphorylated
S6 (pS6) change with TRAIL exposure differentially between cell
lines (Fig 1G). This cell type–specific fractional killing combined with
DR4 correlating to resistance and differential pS6 response to TRAIL
underlines the need to more broadly assay signaling responses to
TRAIL and the relationship to apoptotic escape.
Repeat TRAIL signaling responses are consistent and resistance is
not heritable
Genetic aberrations that confer resistance is selected for by drug
and persists heritably through cell divisions (Klein, 2009; Hu &
Zhang, 2016; Salgia & Kulkarni, 2018). The involvement of nongenetic
mechanisms is revealed by the inability to sustain the resistant
phenotype. Previous work shows that the acquired resistant cell
state cannot persist beyond immediate re-treatment (under 2 d)
with cells resetting and exhibiting similar fractional killing and
transcriptome as cells with no prior exposure to TRAIL (Flusberg
et al, 2013). We built upon these findings by re-treating two known
resistant cell lines of diverse cancer types of cervical and lung
cancer, HeLa C9, and NCIH460, with TRAIL 10 d after an initial
treatment, followed by mass cytometry analysis (Fig 2A, top). Cells
from the two cell lines exhibit similar levels of apoptotic induction
regardless of prior exposure to TRAIL (Fig 2A, bottom). Furthermore,
the resistance potential of a cancer type is conserved across bi-
ological replicates as shown by the conserved frequency of re-
sistant colonies in clonal plating assays (Figs 2B and S2A).
To investigate how regulatory signaling induced by TRAIL changes
with repeat exposure and between cell lines, we built a mass
cytometry panel consisting of known apoptotic proteins and
noncanonical signaling proteins implicated downstream of TRAIL
activation to quantitatively capture behavior in single resistant
cells (Table S1 and Fig 2C). We probed the signaling response of cells
to TRAIL before and after the 10 d “drug holiday” (Fig 2A, top) and
show that they have highly correlated signaling profiles (Figs 2D and
S2C) after repeat exposure. This lack of a differential signaling
memory in TRAIL-resistant cells aligns with the similar apoptotic
and survival cellular responses in these conditions. Importantly, all
non-apoptotic cells, regardless of prior TRAIL exposure, signal in
response to the ligand considering all signaling markers by
t-stochastic neighbor embedding (Fig S2D). However, we note that
this reversible, transient resistant signaling state is not entirely
stochastic and stays consistent across biological replicates (Fig
S2B). The conservation of a resistant signaling response to TRAIL,
regardless of prior exposure, hints at an underlying priming toward
an induced cell survival state previously described in other drug
resistance phenomena (Brown et al, 2014; Smith et al, 2016). Un-
derstanding this state could be key to mitigating apoptotic
resilience.
TRAIL induces cell cycle changes which do not persist or correlate
significantly with resistance
Outside of regulatory cell signaling, another mechanism of drug
resistance can be changes in cell cycle, such as arresting in G1
phase or moving to G0 senescence (Quast et al, 2015; Beaumont
et al, 2016). To investigate the effect of cell cycle on TRAIL resistance,
we gated non-apoptotic cells into the different cell cycle phases
andmapped state changes across a TRAIL treatment time course. In
HeLa C9 cells, we observed changes to cell cycle frequencies with
an increase in G0 cells with a proportional decrease in the S-phase.
This was followed by a return to pretreatment like cell cycle fre-
quencies by 24 h (Figs 3A and S3A) (Behbehani et al, 2012). In-
terestingly, previous work has found TRAIL-mediated proliferation
in resistant cells and higher sensitivity to TRAIL in cell cycle-
arrested cells in different cancer types (Ehrhardt et al, 2013).
Here, the cells adjust to TRAIL exposure and begin to recover their
original cell cycle distributions after 7 h or more of continued TRAIL
exposure (Fig 3A). This time dependency in TRAIL response is seen
for the first time in our work here and highlights the importance of
line indicates a plateau in the fractional killing proportion in the cell line. (D) The live cells at 0 and 6 h of TRAIL treatment is overlaid in dot plots across 10 cell lines with
the percentage of non-apoptotic cells at each time point quantified to calculate the SQ ratio metric. (E) Boxplots show arcsinh-transformed levels of DR4 across cell lines.
(F) Dot plot shows mean abundance of DR4 and SQ across cell lines with Pearson correlation between them. (G) Boxplots of phosphorylated S6 levels in equally
subsampled, untreated and 6 h TRAIL-treated non-apoptotic cells across cell lines.
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appropriate exposure lengths to TRAIL for maximal effect before
stable resistance sets in.
At the same time, a different cancer cell line, HCC827, exhibited
different cell cycle dynamics upon TRAIL exposure as cells moved
out of the G1 state (Fig S3B). To more broadly assess this, we looked
at TRAIL-induced cell cycle changes across all 10 cell lines (Fig 3B).
We found that TRAIL-induced cell cycle changes are cell line de-
pendent with different cell lines increasing in specific cell cycle
phases such as G0 phase for NCIH460, HCC827, and Jurkats; G1 phase
for MDAMB231 and Ntera; and M phase for REH and HeLa C9 (Fig 3B).
TRAIL-induced changes in each cell cycle phase as well as the
combined changes across all phases did not correlate with the SQ
of cell lines (data not shown). Consequently, although TRAIL seems
to have selective effects on cell cycle phase, it appears to be cell
type specific without conserved trends and not related to overall
apoptotic resistance of cells.
Resistant cells persist in a TRAIL-induced signaling state
In the paradigm of preexisting genetic aberrations, resistant cells
are selected for by being refractory (i.e., nonresponsive) to a drug. In
acquired resistance, generally, a subset of cells responds and
moves to the resistant state, whereas the rest move to an apoptotic
state before dying. For the first time, we show evidence for an
Figure 2. Apoptotic resistance is not heritable and TRAIL signaling is reset with each exposure.
(A) Overview of TRAIL re-treatment experiment and dot plots of different re-treatment conditions. The percentage of viable cells in the black non-apoptotic gate is as
shown. (B) Clonogenic analysis of resistance by HeLa C9 cells to TRAIL across three technical replicates and two biological replicates (T1 and T2). (C) Schematic of known
apoptotic and survival signaling pathways downstream of TRAIL receptor. Proteins captured for mass cytometry analysis are in red. (D) Heat map of median abundance of
markers between treated and re-treated samples. Red line indicates significant correlation between values.
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Figure 3. All cells respond but resistant cells persist in a TRAIL-induced signaling state.
(A) Line graph of four cell cycle phases tracking percentage of viable HeLa C9 cells in the four cell cycle phases from 0 to 24 h of TRAIL exposure. (B) Heat map of fold
change in percentage of non-apoptotic cells in cell cycle gate between untreated and 6 h TRAIL treatment scaled by column. (C) Heat map is individually scaled column-
wise and colored by the arcsinh ratio relative to 0-h treatment to illustrate the increase or decrease of marker relative to basal state in non-apoptotic HeLa C9 cells.
(D) viSNE representation of 20 K equally subsampled signaling states of cells moving from basal, through TRAIL-induced state to apoptotic state across time points (red
arrows). Maps are colored by cPARP and phosphorylated S6 levels. Black arrow indicates cells that persist in the TRAIL-induced state. (E) Heat map colored by coefficient
of variation of individual markers in equally subsampled, non-apoptotic HeLa C9 cells from 0 to 24 h of TRAIL exposure (individually scaled column-wise). (F) Dot plot
shows mean signaling diversity and SQ across time course of TRAIL treatment and Pearson correlation between them.
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alternative trajectory of acquired resistance where all cells respond
and move to a survival signaling state, but only a subset persists in
it over time and remains resistant with the remaining cells pro-
gressing to an apoptotic state (Fig S3E).
We captured the single-cell responses to increasing exposure of
TRAIL with our mass cytometry panel and charted the signaling
differences from untreated cells (Table S1 and Fig 3C). Many of the
survival signaling proteins have increased activity with higher levels
of phosphorylation after 2 h of TRAIL exposure (Fig 3B). The higher
abundance of RSK2 kinase and phosphorylated p38 kinase is not
sustained with increasing exposure to TRAIL (Fig 3C). The RSK2
kinase is a known modulator of S6 kinase activity and has been
implicated in TRAIL-induced apoptosis through its phosphorylation
and subsequent degradation of pro-apoptotic protein caspase 8
(Panner et al, 2005; Peng et al, 2011). Although RSK2 might be crucial
in mounting resistance to initial exposure to TRAIL, as the cells
tolerize to TRAIL and persist with time, it is likely not required to
maintain the resistant signaling state (Fig S3E). Similarly, activated
p38 kinase is a crucial survival signaling protein that is known to
increase within 2 h of TRAIL exposure, but we show that this does
not persist with more prolonged exposure (Fig 3C) (Piras et al, 2011).
Only two survival signaling proteins, AKT and S6 kinases, are up-
regulated and show higher than basal levels of activation after 5 h
of TRAIL exposure (Fig 3B). This supports the known role of AKT and
its regulation of mTOR and, therefore, S6 kinase in the maintenance
of the TRAIL resistance state (Xu et al, 2010). Other signaling pro-
teins, such as NFkB, have dual roles in TRAIL resistance. It has been
shown that NFkB not only promotes death receptor expression but
also increases expression of apoptosis inhibitor Bcl-xL (Ravi et al,
2001; Luo et al, 2005). The specific levels and activity of the signaling
and apoptotic markers we captured are essential in modulating
anti- or pro-apoptotic responses to TRAIL.
We mapped the high-dimensional signaling response to TRAIL
into lower dimensions using t-stochastic neighbor embedding to
visualize the different cellular states and the frequency of cells in
each state with increasing exposure to TRAIL (Figs 3D and S3D) (Amir
et al, 2013). We identified three distinct states from our signaling
markers: a basal state, a TRAIL-induced state, and an apoptotic
state (Figs 3D and S3D). The time course here demonstrates that
virtually all cells respond to TRAIL by moving from the basal state to
a TRAIL-induced signaling state (Figs 3D and S3D). However, this
state transition is not immediate; the cells only move to the TRAIL-
induced signaling state around 4 h, and are likely tolerized to TRAIL
after 7 h, which is reflected in cell cycle changes andmarker variance
(Fig 3A and E). It is from this intermediate state that a proportion of
cells persist and do not progress to apoptosis, even with continued
TRAIL exposure (Fig 3D, black arrow). This latter transition is likely
dependent on a caspase cleavage cascade in late apoptosis acti-
vation that we further confirmed by applying a caspase inhibitor
which prevented most cells from undergoing this terminal process
(Fig S3C). Our ability to inhibit death by TRAIL indicated a potentially
ordered process of cellular response to TRAIL; therefore, we sought
to model the cellular response to TRAIL as a trajectory.
Our results suggested a linear progression from a basal to TRAIL-
induced signaling state where cells either persist or proceed to
apoptosis (Figs 3D and S3D). We captured the signaling progression
from basal to TRAIL-induced resistant state by building a linear,
pseudo-time trajectory of non-apoptotic cells across time points with
the Wanderlust algorithm (Fig S3E and F) (Bendall et al, 2014a). The
constructed trajectory revealed the rapid transitions that cells un-
derwent in specific signaling proteins and showed the specific states
that cells remained in without progressing to apoptosis (Fig S3D and E).
Given the asynchrony of apoptotic progression, this trend was not
surprisingly hidden within time-based fold change analysis on bulk
populations (Fig 3C) (Spencer et al, 2009). This not only highlights the
need for high-throughput single-cell techniques to model such
processes, but also further emphasizes the previously overlooked role
of noncanonical signaling in resistance to TRAIL-induced apoptosis.
We see a similar pattern of time dependency seen in the cell
cycle and signaling response in the variance of markers across the
TRAIL time course (Figs 3A, S3D, and 3E). Variation is known to be
implicated in nongenetic mechanisms of resistance to TRAIL (Spencer
et al, 2009; Frank&Rosner, 2012). Signaling protein abundances aswell
as their variation changed with exposure to TRAIL (Fig 3C and E). The
signaling markers are relatively homogenous at short exposures.
However, with increasing exposure, the variation in signaling markers
also increases and then decreases towards baseline at 24 h. The
highest variation across all markers is seen around 4–7 h of TRAIL
exposure and coincides with stabilization of the frequency of TRAIL-
resistant cells and full shift to the TRAIL-induced signaling state (Figs
1C and 3E, and S3D). We calculated the variation of individual signaling
proteins using coefficient of variation and we calculated the overall
signaling state diversity with Shannon diversity index on unit-scaled
arcsinh-transformed signaling marker counts. We saw a highly sig-
nificant positive correlation between resistance (SQ) and diversity of
signaling states in non-apoptotic cells (Fig 3F). Variation is likely
playing a role in the noncanonical survival signaling response and,
therefore, resistance to TRAIL-induced apoptosis.
Signaling diversity in response to TRAIL correlates with resistance
to apoptosis
To identify conserved mechanisms of resistance in the signaling
response to TRAIL, we expanded our analysis of single-cell TRAIL
responses at 6 h to 10 cell lines and compared the fold change in
signaling markers from untreated condition (Fig 4B). Much like the
cell cycle behavior in response to TRAIL, the signaling responses
were fairly cell line specific and with some conservation in IkBalpha
and pS6 (Fig 4B). As expected, based on canonical TRAIL signaling
(Fig 2C), most cell lines generally increased NFkB through decreasing
its inhibitor IkBalpha as well as up-regulating phosphorylated S6,
presumably through upstream mTOR or AKT activation (Fig 4B).
To more broadly identify signaling modalities in TRAIL-resistant
cells, we clustered non-apoptotic cells after 6 h of TRAIL treatment
and found eight different signaling states (Fig S4A, left). These
clusters were similar in levels of p4EBP1, pS6, pMAPKAPK, and total
S6, but each cluster was also generally dominated by a single cell
line (Fig S4A). The resistant state with the most substantial number
of cells (cluster 1) is made up of a few cell lines such as HeLa C9,
HCC827, and HeLa and has relatively high levels in more than half of
the signaling markers (Fig S4A, right). However, no signaling state
was present across all TRAIL-sensitive cell lines that represented a
conserved state of resistance from which one could deduce a
mechanism pertaining to one or more signaling proteins.
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Figure 4. TRAIL-induced change in cell signaling entropy correlates with apoptotic resistance across cell types.
(A) Schematic of single-cell analysis carried out across cell lines (B) Heat map of arcsinh fold changes of median abundances of signaling marker between 0 and 6 h of
TRAIL-treated non-apoptotic cells. Heat map rows and columns ordered by hierarchal clustering. (C) Differential Pearson correlation between signaling marker
abundance in untreated and 6-h TRAIL–treated non-apoptotic HeLa C9 cells. (D) Differential Pearson correlation between signalingmarker abundance in untreated and 6-
h TRAIL–treated non-apoptotic NCIH460 cells. (E) Boxplots showingmedian signaling diversity calculated over 14 markers (Table S1) across cell lines (with 1–4 biological
replicates). (F) Dot plot showing median signaling diversity and SQ across cell lines in untreated cells (left) and in 6-h TRAIL–treated cells (right) with Pearson correlation
coefficient and P value displayed.
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With this in mind, we sought to quantify signaling diversity and
understand the relationships between the signaling markers in our
assayed cell lines to find what might correlate with the SQ of cell
lines from our mass cytometry readout of multiplexed, single-cell
signaling response to TRAIL (Fig 4A). Cell lines did not drastically
differ in their signaling marker correlations before and after TRAIL
treatments in individual lines; however, across cell lines, they do
show differences in marker correlations (Figs 4C and D, S4B–E, and
S5A–D). Phosphorylated ERK (extracellular signal-regulated kinase),
IkBalpha, and P90RSK show stronger positive correlations with many of
the other signaling markers after 6 h of TRAIL treatment (Fig 4A). Sig-
naling proteins in NCIH460 show different correlation patterns as can
be seen from the different hierarchal arrangement of markers (Fig 4D).
There is no conserved pattern of signaling protein relationship across
cell lines to identify a universal signaling modality in TRAIL resistance.
Therefore, we hypothesized that the overall cell signaling het-
erogeneity in the noncanonical response to TRAIL might be important
to resistance (Spencer et al, 2009; Roux et al, 2015). We quantified the
signaling diversity in non-apoptotic cells after 6 h of TRAIL resistance
across our 10 cell lines (Fig 4E). Different cell lines showed different
resulting diversity upon TRAIL exposure, with Jurkats showing the
lowest diversity (Fig 4E). Specifically, signaling diversity after TRAIL
treatment and not before correlated significantly with resistance to
TRAIL (SQ), showing that TRAIL might be inducing signaling diversity
(Fig 4F). There is a likely a nonlinear relationship hinting at a resistance
threshold that once reached, cells have similar signaling diversities
regardless of cell type (Fig 4F). Therefore, it is specifically the induction
of variation by TRAIL that underlies the acquisition of resistancewhere
the higher the diversity of signaling states induced by TRAIL, the higher
the ability of the population to persist in the resistant state without
progressing to apoptosis.
Constricting signaling space of TRAIL responses decreases
apoptotic resistance
We were able to relate TRAIL-induced signaling entropy to apo-
ptotic resistance and, therefore, hypothesized that constricting the
diversity in survival pathway responses to TRAIL would lead tomore
cells progressing to apoptosis. To restrict permissible signaling
states, we combined TRAIL with various kinase inhibitors to critical
signaling proteins downstream of TRAIL activation (Fig 5A). Our
combination of inhibitors changed the fractional killing frequency
of cells and resulted in similar or lower SQs (Fig 5B and C, in green).
Interestingly, the signaling response of two cell lines to the com-
bination treatments of TRAIL and inhibitors differed dramatically
with HeLa C9 showing a much stronger up-regulation of signaling
than NCIH460 (Figs 5D and S6A). Inhibitors to p38, PI3K, and mam-
malian target of rapamycin (mTOR), showed compensatory signaling
changes in AKT, AMPK, andHSP27 and expected reduction in pAKT with
PI3K inhibition and reduction in pS6 withmTOR inhibition (Figs 5D and
S6A). These complex changes in signaling modalities in response to
combination TRAIL and inhibitor treatments create challenges in
predicting resistant states and level of fractional killing. As such,
population-level characteristics of single-cell abundances such as
individual marker variation and high-dimensional signaling di-
versity offer a more robust assessment of cellular responses and
prediction of apoptotic response to inhibitor combinations.
Here, we observe that the combination treatments on two cell
lines, HeLa C9 and NCIH460, change the marker variation by restricting
permissible signaling state cells that can occupy when only exposed to
TRAIL (Figs 5B, E, and C, and S6B for each cell line respectively). Cells are
forced to occupy different signaling states, and markers show higher
variation especially with P38 and JNK inhibitors (Fig 5B and E). However,
when we look at the overall signaling diversity across markers and in
two cell lines, we see a significant positive correlation betweendiversity
induced by combination therapy and the resulting difference in re-
sistance (Fig 5F). This is in line with our previous observation that the
induction of signaling diversity by TRAIL is linked to greater resistance
to apoptosis (Figs 4F and 5F). Overall, these data demonstrate that
signaling diversity couldbeusedas ametric to quantify permissible cell
state space of resistance and, therefore, predict the level of fractional
killing and efficacy of combination inhibition (Cheng et al, 2016).
We further dug into the relationship between signaling proteins by
looking at the differential correlation between cells treated with only
TRAIL or with combination therapy (Figs 5G and S6C–E). Interestingly,
phosphorylated IkBalpha and AMP-activated protein kinase (AMPK)
showed themost different correlations withmTOR inhibition (Fig 5G).
There was an increase in mutual information between phosphory-
lated IkBalpha and nuclear factor kappa-light-chain-enhancer of
activated B cells (NFkB), indicating that cells are signaling more
strongly through the NFkB pathway and less strongly between
phosphorylated AMPK and NFkB in response to mTOR inhibition (Fig
5H). We are able to broadly capture signaling protein relationships
and signaling pathway flux with our high-dimensional signal cell data
to better understand combination treatment with TRAIL.
TRAIL signaling induced de novo translation is correlated with
increased signaling and apoptotic escape
Because ribosomal protein S6 phosphorylation seen here (Fig 1G) is
an indicator of translational activity, we hypothesized that differ-
ences in translation ratemight be linked to the diversity of signaling
states and contribute to TRAIL resistance. Previous work has shown
the efficacy of treating cancer cells with a combination of TRAIL and
the protein synthesis inhibitor, cycloheximide, to maximize the
apoptotic response (Mori et al, 2005; Spencer et al, 2009). Here, we
treated the cells with cycloheximide at a subcytotoxic dose with or
without TRAIL. By itself, cycloheximide did not induce apoptosis, but
when combined with TRAIL, it resulted in almost no surviving cells
(Figs 6A and S7A) (Mori et al, 2005; Spencer et al, 2009).
To understand the relationship between protein synthesis and
resistance to TRAIL-induced apoptosis across cell lines and combi-
natorial inhibition, we simultaneously captured the relative rate of de
novo translation using a novel single-cell reporter in our panel of
signaling and apoptotic markers (see the Materials and Methods
section) (Kimmey et al, 2019). Interestingly, this revealed that the
TRAIL-responsive, yet resistant, cells exhibited high levels of de novo
translation, which could be abrogated by additional cycloheximide
(Figs 6B and S7B, black arrows). Similarly, the cells that remained non-
apoptotic after kinase inhibition also exhibited high rates of trans-
lation (Fig S7C and D, black circle) even in cases where combination
treatment with kinase inhibitor has a protective effect from TRAIL (i.e.,
mTOR inhibition). Untreated cells do not have as high puromycin
levels as compared with TRAIL or combination therapy treated cells
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Figure 5. Combination therapies decrease resistance to TRAIL by restricting signaling diversity.
(A) Overview of experiment to test combination therapy of TRAIL with kinase inhibitors targeted at key survival signaling proteins. (B) Dot plots showing apoptotic
induction in viable HeLa C9 cells with cCasp3 and cPARP with combination therapies in HeLa C9 cells and SQ shown in green. (C) Dot plots showing apoptotic induction in
viable NCIH460 cells with cCasp3 and cPARP with combination therapies in HeLa C9 cells and SQ shown in green. (D) Heat map of arcsinh fold change of median signaling
marker abundance in non-apoptotic HeLa C9 cells between combination treatments and TRAIL treatment only scaled by markers. (E) Heat map signaling marker
variation (calculated by coefficient of variation) in non-apoptotic HeLa C9 cells scaled column-wise by markers. (F) Dot plot showing fold change in median signaling
diversity and fold change in SQ between only TRAIL and combination therapy treatments with Pearson correlation calculated between them. (G) Differential correlation of
signaling markers between 6-h TRAIL treatment and mTOR inhibitor combination therapy in non-apoptotic HeLa C9 cells. (H) Top differentially correlated marker pairs
from Fig 5G visualized on conditional-Density Resampled Estimate of Mutual Information (DREMI) plots with their scaled mutual information shown.
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suggesting TRAIL treatment was inducing an increase in translation
through the noncanonical signaling response (Fig 6B and C). We see
that the resistant cells have distinct low and high translating pop-
ulations that correspondingly have low and high signaling markers
across combination therapies suggesting a likely feedback loop be-
tween translation and these key signaling proteins (Figs 6C and S7E).
Furthermore, particularly in cell linesmore sensitive to TRAIL (i.e.,
Jurkat and HeLa C9), translation rates are much more increased in
the non-apoptotic cells after TRAIL treatment (Fig 6D). These data
illustrate how translation could be producing protein survival
factors that further increase translation to produce a positive
feedback loop that keeps cells in the noncanonical response and
evading TRAIL-induced apoptosis. Overall, we examine TRAIL re-
sponse in 10 different cell lines and show how TRAIL-induced
signaling diversity and translation correspond to resistance to
TRAIL-induced apoptosis (Fig 6E).
Figure 6. TRAIL-induced increase in translation is linked to apoptotic resistance.
(A) Dot plots showing apoptotic induction (percentage of live, viable cells, in black) in HeLa C9 cells with combination therapy of cycloheximide (protein synthesis
inhibitor) and TRAIL (SQ shown in green). (B) Dot plots showing puromycin levels that track single-cell translation rate in viable HeLa C9 cells with combination therapy of
cycloheximide and TRAIL. (C) Dot plots showing phosphorylated S6 and NFkB in non-apoptotic HeLa C9 cells across combination inhibitor treatments with puromycin
levels in color overlay. (D) Histograms of puromycin levels in non-apoptotic cells across cell lines. (E) Summary schematic of paper showing role of signaling diversity
and translation in resistance to TRAIL-induced apoptosis.
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Discussion
Here, we highlight the role of variation and protein synthesis in the
noncanonical signaling response to TRAIL and how it relates to escape
from TRAIL-induced apoptosis (Fig 6E). We demonstrate that despite
uniform activation across TRAIL-responsive cell lines, the frequency of
cells resistant to apoptosis was highly variable. Moreover, resistant
signaling states are not present before TRAIL treatment and are,
therefore, not selected for. Instead, TRAIL induces different signaling
states across cell lines and the overall change diversity upon treat-
ment correlates with apoptotic resistance at the population level. By
constricting the diversity of achievable TRAIL-induced signaling states
with kinase inhibitors, we could also concomitantly decrease re-
sistance and increase progression to apoptosis. This was directly
associatedwith denovoprotein synthesis in response to TRAIL that we
demonstrated was required for apoptotic escape.
The mechanisms by which cancer cells successfully evade the
action of cell death–inducing therapies ultimately lead to most
cancer fatalities. The traditional understanding of resistance is
where genetic aberrations confer a selective advantage on a subset
of the population is insufficient to explain resistance (Cohen et al,
2008; Lee et al, 2012). Here, we add to the role of nongenetic
mechanisms in driving resistance and the probability of multiple
disparate mechanisms of resistance acting concurrently to confer
resistance (Frank & Rosner, 2012). Integrating information on var-
ious sources of resistance will help us better model resistance to
drugs such as TRAIL which is plagued by unexplainable clinical
inefficacy. To date, resistance to TRAIL therapy is still debated in
part because of the engagement of multiple canonical and non-
canonical signaling pathways downstream of TRAIL. The complex
interplay between these and the resulting heterogeneity in cellular
and patient responses confounds this understanding further.
With this in mind, previous studies have taken clonal, single-cell
approaches to establishing a more systemic resistance mechanism.
For instance, preexisting variation in essential apoptotic proteins in
individual cells due to stochasticity has been previously implicated in
TRAIL resistance (Spencer et al, 2009). This supports the view that
nongenetic resistance to TRAIL is driven by the Darwinian selection of
preexisting cellular features such as protein levels. However, there is a
growing body of literature that characterizes a Lamarckian induction
of cellular features that allow a cell to become resistant upon ex-
posure to the drug (Pisco et al, 2013; Fallahi-Sichani et al, 2017; Shaffer
et al, 2017). Here, we were able to show for the first time that acquired,
nongenetic mechanisms such as induction of survival signaling and
variation in it upon TRAIL exposure allows different cell linemodels to
variably persist and achieve a stable, TRAIL resistant state. This was
uniquely possible through our utilization of highly multiplexed single-
cell signaling assays to characterize the apoptotic response to TRAIL
using mass cytometry (Bendall et al, 2011).
Variation in signaling is known to confer robustness at the
population level and allow differential responses to the same
stimuli (Schaefer et al, 2014). Therefore, it is logical to consider that
the more diverse the signaling states present in a population, the
more robust it is to environmental stimuli. We see this with in-
creased induction of variation in signaling correlating with in-
creased resistance to TRAIL at the population level. By changing the
diversity of signaling states of response using kinase inhibitors, we
showed that cells were concomitantly less robust and more sensitive
toward TRAIL. We quantified high-dimensional heterogeneity in sig-
naling states using Shannondiversity index, andwepurport thatwecan
use this index as a combination therapy design tool (Huang et al, 2017).
Given the crucial role of induced variation in TRAIL resistance,
what might underlie and drive this diversity? We show that higher
levels of de novo translation in TRAIL-resistant cells is directly
associated with the variable TRAIL-induced signaling state. Thus,
the requirement of translation for TRAIL resistance combined with
the associated signaling variability implicates translation induced
by TRAIL as a key contributor to the diversity in resistant states. A
potential link between the population-level behavior in fractional
TRAIL killing, and intracellular control of translation could be that
viable population density might be influencing intracellular sig-
naling pathways that promote translation. The relationship be-
tween cell density and drug resistance has been previously
researched in other drugs, where the Hippo-yes-associated protein
1 pathway has been characterized as a molecular link (Pernicova´
et al, 2014; Gujral & Kirschner, 2017; von Manstein & Groner, 2017).
Contact inhibition in TRAIL resistance and its link to translation is
yet unexplored andmight better informmodels of TRAIL resistance.
Apart from translation, epigenetic heterogeneity is also likely
driving differential signaling states. The epigenome controls chro-
matin accessibility to transcription machinery and subsequently in-
fluences protein synthesis and final cell state. The link between the
chromatin accessibility profile and cell state is known, and therefore,
preexisting variation in chromatin state could explain the variation in
TRAIL-induced cell states (Lara-Astiaso et al, 2014). Poised chromatin
states have been shown to lead to drug-tolerant reversible states with
more prolonged exposure permanently altering the epigenome to
allow for more stable resistance (Sharma et al, 2010; Brown et al, 2014).
Single-cell technologies that capture chromatin accessibility profiles
such as single-cell Assay for Transposase-Accessible Chromatin using
sequencing could help explore the influence of epigenomic variability
on the heterogeneity of resistance to cancer drug such as TRAIL
(Buenrostro et al, 2015; Litzenburger et al, 2017). Still, our data indicate
that this state cannot be selected for in the short term, suggesting that
this epigenetically TRAIL-resistant state, if it exists, is part of a con-
tinuum of states whose abundance is cell type specific. Future work
could investigate for common themes in regulatory epigenetic ele-
ments downstream of TRAIL-induced signaling.
Altogether, we applied a single cell, high-dimensional systems
biology approach to study TRAIL resistance which led to us iden-
tifying diversity of signaling states as a new, conserved nongenetic
mechanism of resistance to TRAIL. This nongenetic resistance study
encourages further work to identify and understand its funda-
mental drivers and explore its role in other drugs and cell death
inducing ligands beyond TRAIL.
Materials and Methods
Cell culture
HeLa C9, Ntera2, and MDAMB231 cells were cultured in DMEM con-
taining 10% FBS and 1% penicillin/streptomycin (Gibco). NCIH460,
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Jurkats, REH, U937, HEL, and HCC827 cells were cultured in RPMI
containing 10% FBS, 5mM L-glutamine and 1%penicillin/streptomycin
(Gibco). HCT116 cells were cultured in McCoy’s media containing 10%
FBS and 1% penicillin/streptomycin (Gibco). The cells were treated
with TRAIL when they were at 60–70% confluency to exclude density-
dependent effects on resistance to TRAIL-induced apoptosis.
Mass cytometry experiments
The cells were treated with SuperKiller TRAIL (Enzo Life Sciences; 50
ng/ml) for indicated times. In all experiments involving pertur-
bagens, the cells were pretreated either with DMSO or with the
following perturbagens 1 h before application of TRAIL: JNK Inhibitor
I (EMD Millipore; 2 μM), Ku-0063794 (Selleck Chemicals; 1 μM),
SB203580 (Cell Signaling Technology; 20 μM), and GDC-0941 (Selleck
Chemicals; 2.5 μM).
The cells were treated with 10 μM IdU (Sigma-Aldrich) (Behbehani
et al, 2012) and 10 μM puromycin (Kimmey et al, in press) for 30 min
before harvesting. IdU is used to label dividing cells in the S phase as
DNA replication occurs (Behbehani et al, 2012). Puromycin is used as
label to tag nascent peptides in ribosomes for a single-cell translation
rate tracking technique, which quantifies the level of puromycin per
cell using a metal isotope-tagged monoclonal antibody to puromycin
on mass cytometry (Kimmey et al, 2019).
To halt survival and apoptotic signaling, the cells were fixed with
formaldehyde (PFA; Electron Microscopy Sciences) added directly
to growth media at a final concentration of 1.6% for 10 min at room
temperature and washed twice with staining media (PBS with 0.5%
BSA, 0.02% sodium azide) to remove residual PFA. Cells were
permeabilized with methanol for 10 min at 4°C, then optionally
stored at −80°C for later use. The cells were then washed twice in
cell staining media to remove remaining methanol and stained for
intracellular proteins for 30 min at room temperature. Staining
cocktails are listed in Table S1. The cells were washed with CSM and
stained with 1 ml of 2000× Ir DNA intercalator (diluted 1:5,000 in PBS
with 1.6% PFA; DVS Sciences) for 20 min at room temperature or
overnight at 4°C. Before CyTOF analysis, the cells were washed once
with CSM and then twice with ddH2O.
Clonogenic assays
Clonogenic assays were carried out in triplicate. Cells growing in log
phase were plated in six-well plates at the following densities: HeLa
cells—2,000 cells/well, HCT116 cells—10,000 cells/well, and
NCIH460—1,000 cells/well under standard cell culture conditions.
TRAIL or DMSO was added to the culture media 24 h after plating at
the concentrations listed above, the plates were incubated in cell
culture incubators for 1 h and TRAIL 50 ng/ml was added, and the
plates were incubated in cell culture incubators for 24 h. The plates
were then washed two times with 37° medium and the medium was
refreshed. The cells were then cultured until each colony contained
at least 50 cells. Colonies were stained with crystal violet and
counted using a light box. For serial passage experiments, HeLa C9
cells were plated out in 25-cm2 flasks at 4 × 105 cells and treated in
parallel with clonogenic assays under identical conditions. Cells
from flasks plates were then passaged two times over 10 d, plated
for clonogenic assays, re-treated with the same conditions, and
analyzed.
TRAIL receptor (DR4) flow cytometry experiments
Endogenous cell lines were grown to 60% confluency and harvested
before fixing with 1.6% PFA for 10min. Fixed cells were stained with 4
μg/ml of TRAIL receptor 1 primary antibody (Catalog number AF347
from R&D systems) and anti-goat secondary antibody conjugated
to Alexa 488 (ab150129; Abcam) for 30 min each at room temper-
ature. Titration data and unstained and secondary stained controls
are shown in Fig S1.
Mass cytometry analysis data preprocessing
To make all samples maximally comparable, data were acquired
using internal metal isotope bead standards as previously de-
scribed (Finck et al, 2013). Cell events were acquired at ~300 events
per second on a CyTOF (DVS Sciences) using instrument settings
previously described (Finck et al, 2013). Each sample was individually
normalized to the internal bead standards before analysis. To remove
post-apoptotic cells and debris, the cells were gated based on cell
length and DNA content (Bendall et al, 2011). Mass cytometry dot plots,
histograms, and heat maps were created either on www.cytobank.org
or R with signal strength displayed on an arcsinh scale (the inverse
hyperbolic sine) (Chen & Kotecha, 2014).
viSNE analysis
All viSNE analyses were performed on Cytobank with equal sub-
sampling of 20 K non-apoptotic cells per sample across the time
course with standard settings of 1,000 iterations, perplexity of 30,
and θ of 0.5 (Amir et al, 2013; Chen & Kotecha, 2014).
Wanderlust analysis
Non-apoptotic HeLa C9 cells after 0–8 h of TRAIL treatment were
equally subsampled to 5 K cells from each sample and concate-
nated into one CSV file before building a linear trajectory based on
the signaling markers using the Wanderlust implementation on
MATLAB (Bendall et al, 2014a). The first derivative of output signaling
changes was visualized along the calculated trajectory. The output
CSV file had an extra columnwith a wanderlust score between 0 and
1 for every non-apoptotic cell from the pooled time course. The cells
were binned according to their wanderlust score and visualized as a
histogram on R.
Signaling diversity calculation
The non-apoptotic cell populations of interest were gated on
Cytobank and exported into R. 10 K cells from each file was sub-
sampled and arcsinh transformed. 14 markers were selected
(shown in Table S1) and the counts were scaled between 0 and 1.
Shannon diversity index was then calculated over the data matrix
using the Euclidean distance metric. The median diversity index per
sample was then correlated to the calculated SQ of each cell line
using Pearson correlation.
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Statistical work and visualizations in R
ggplot2 package was used for visualizing data with dot plots and
boxplots. Correlation between markers on arcsinh-transformed
data values was carried out using Spearman correlation with the
DCGA package. Heat maps were made with heatmap.2 function from
the gplots package. Mutual information (DREMI) scores and plots
were created using the scprep stats toolkit (Krishnaswamy and
Spitzer, 2014).
Data availability
All live cell gated data in FCS files are publicly available on
flowrepository.org with the following IDs: FR-FCM-Z276, FR-FCM-
Z277, FR-FCM-Z278, FR-FCM-Z279, FR-FCM-Z27A, FR-FCM-Z27B, FR-
FCM-Z27C, FR-FCM-Z27D and FR-FCM-Z27E.
Supplementary Information
Supplementary Information is available at https://doi.org/10.26508/lsa.
201900554.
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